Andrew Mastro, MS, PA-C, outlines the proper clinical application of ruxolitinib cream 1.5% as a noncontinuous topical treatment for mild-to-moderate atopic dermatitis in nonimmunocompromised patients aged at least 2 years. Specific guidelines are provided for body surface area limits, weekly tube quantity restrictions, and the recommendation to stop application once symptoms resolve or re-evaluate if no improvement occurs within 8 weeks. Mastro shares clinical observations showing that ruxolitinib provides rapid itch relief and helps patients reduce reliance on topical corticosteroids or delay systemic therapies.
Topics Covered:
- Ruxolitinib prescribing guidelines, age-specific quantity limits, and dosing rules
- Clinical benefits of nonsteroidal treatment for mild-to-moderate atopic dermatitis
- Strategies for patient communication regarding disease flares and boxed safety warnings
